Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F Moore

Showing results (1031-1040 of 1,231) with videos related to

Pageof 124
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 22, 2003
Gemcitabine and oxaliplatin for metastatic pancreatic adenocarcinoma: a North Central Cancer Treatment Group phase II studyS R Alberts, P M Townley, R M Goldberg, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 20, 2007
Gemcitabine, cisplatin, and radiotherapy for patients with locally advanced pancreatic adenocarcinoma: results of the North Central Cancer Treatment Group Phase II Study N9942Michael G Haddock, Revathi Swaminathan, Nathan R Foster, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 10, 2023
Open-label, phase II, multicenter study of lasofoxifene plus abemaciclib for treating women with metastatic ER+/HER2- breast cancer and an ESR1 mutation after disease progression on prior therapies: ELAINE 2S Damodaran, C C O'Sullivan, A Elkhanany, et al.
Cancer Medicine|December 21, 2022
Addressing multilevel barriers to clinical trial participation among Black and White men with prostate cancer through the PACCT studySusan Eggly, Nicole Senft, Seongho Kim, et al.
Clinical Lung Cancer|August 13, 2017
Paired Phase II Studies of Erlotinib/Bevacizumab for Advanced Bronchioloalveolar Carcinoma or Never Smokers With Advanced Non-Small-cell Lung Cancer: SWOG S0635 and S0636 TrialsHoward L West, James Moon, Antoinette J Wozniak, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 7, 2007
Phase III trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia: US Intergroup Trial E2997Ian W Flinn, Donna S Neuberg, Michael R Grever, et al.
International Journal of Radiation Oncology, Biology, Physics|March 6, 2007
Phase I North Central Cancer Treatment Group Trial-N9923 of escalating doses of twice-daily thoracic radiation therapy with amifostine and with alternating chemotherapy in limited stage small-cell lung cancerYolanda I Garces, Scott H Okuno, Steven E Schild, et al.
Veterinary Immunology and Immunopathology|July 10, 1998
Analysis of the immunological cross reactivities of 213 well characterized monoclonal antibodies with specificities against various leucocyte surface antigens of human and 11 animal speciesR Brodersen, F Bijlsma, K Gori, et al.
Cancer|June 11, 2008
Low-dose, single-agent temsirolimus for relapsed mantle cell lymphoma: a phase 2 trial in the North Central Cancer Treatment GroupStephen M Ansell, David J Inwards, Kendrith M Rowland, et al.
Annals of the Rheumatic Diseases|August 26, 1998
HLA-DRB1 typing in rheumatoid arthritis: predicting response to specific treatmentsJ R O'Dell, B S Nepom, C Haire, et al.
Pageof 124

Showing results (1031-1040 of 1,231) with videos related to

Sort By:
Pageof 124
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 22, 2003
Gemcitabine and oxaliplatin for metastatic pancreatic adenocarcinoma: a North Central Cancer Treatment Group phase II studyS R Alberts, P M Townley, R M Goldberg, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 20, 2007
Gemcitabine, cisplatin, and radiotherapy for patients with locally advanced pancreatic adenocarcinoma: results of the North Central Cancer Treatment Group Phase II Study N9942Michael G Haddock, Revathi Swaminathan, Nathan R Foster, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 10, 2023
Open-label, phase II, multicenter study of lasofoxifene plus abemaciclib for treating women with metastatic ER+/HER2- breast cancer and an ESR1 mutation after disease progression on prior therapies: ELAINE 2S Damodaran, C C O'Sullivan, A Elkhanany, et al.
Cancer Medicine|December 21, 2022
Addressing multilevel barriers to clinical trial participation among Black and White men with prostate cancer through the PACCT studySusan Eggly, Nicole Senft, Seongho Kim, et al.
Clinical Lung Cancer|August 13, 2017
Paired Phase II Studies of Erlotinib/Bevacizumab for Advanced Bronchioloalveolar Carcinoma or Never Smokers With Advanced Non-Small-cell Lung Cancer: SWOG S0635 and S0636 TrialsHoward L West, James Moon, Antoinette J Wozniak, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 7, 2007
Phase III trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia: US Intergroup Trial E2997Ian W Flinn, Donna S Neuberg, Michael R Grever, et al.
International Journal of Radiation Oncology, Biology, Physics|March 6, 2007
Phase I North Central Cancer Treatment Group Trial-N9923 of escalating doses of twice-daily thoracic radiation therapy with amifostine and with alternating chemotherapy in limited stage small-cell lung cancerYolanda I Garces, Scott H Okuno, Steven E Schild, et al.
Veterinary Immunology and Immunopathology|July 10, 1998
Analysis of the immunological cross reactivities of 213 well characterized monoclonal antibodies with specificities against various leucocyte surface antigens of human and 11 animal speciesR Brodersen, F Bijlsma, K Gori, et al.
Cancer|June 11, 2008
Low-dose, single-agent temsirolimus for relapsed mantle cell lymphoma: a phase 2 trial in the North Central Cancer Treatment GroupStephen M Ansell, David J Inwards, Kendrith M Rowland, et al.
Annals of the Rheumatic Diseases|August 26, 1998
HLA-DRB1 typing in rheumatoid arthritis: predicting response to specific treatmentsJ R O'Dell, B S Nepom, C Haire, et al.
Pageof 124